Egypt’s Psoriasis drug market size stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Psoriasis is a chronic, immune-mediated inflammatory skin disease, which ranges in severity (depending on inheritance and environmental factors) from a few scattered reds, scaly plaques to the involvement of almost the entire body surface. It may progressively worsen with age or wax and wane in its severity.
In Egypt, the prevalence of psoriasis is about 3-4%. Statistics indicate that there are more than one million Egyptian patients, of which 145,000 are moderate and severe. People with psoriasis report physical pain and seriousness of the disease, as well as its adverse emotional effects. Further, psoriasis has severe psycho-social impacts on the patient as they refuse any close social bond, leading to poor psychosocial adjustment.
The traditional single-drug therapy has side effects and therefore a combination of various psoriasis drugs is used to treat patients. The introduction of several novel psoriasis drugs and advanced techniques is fuelling the demand for combination therapies and may boost the growth of the psoriasis drugs market consequently. Owing to these factors growth in revenue generation for the psoriasis drugs market has been registered.
With the rise in prevalence of the disease, people are more aware than ever and seek treatment. This is naturally expected to boost the growth in the psoriasis treatment market.
In 2019, the Ministry of Health in Egypt approved the first biological treatment of moderate to severe plaque psoriasis patients. This treatment offers psoriasis patients both effective and long-lasting control of this disease’s symptoms.